ALXN 1910
Alternative Names: ALXN-1910Latest Information Update: 14 Mar 2023
At a glance
- Originator Alexion AstraZeneca Rare Disease
- Class
- Mechanism of Action Alkaline phosphatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bone disorders
Most Recent Events
- 07 Feb 2023 Alexion completes a phase I trial in Bone disorders (In volunteers) in United Kingdom (IV) (NCT05307978)
- 07 Feb 2023 Alexion completes a phase I trial in Bone disorders (In volunteers) in United Kingdom (SC) (NCT05307978)
- 12 Apr 2022 Phase-I clinical trials in Bone disorders (In volunteers) in United Kingdom (IV) (NCT05307978)